#None #Werfen #GEM Premier 7000 #iQM3

Werfen's Expansion of GEM Premier 7000 with iQM3 to Europe

Introduction
Werfen has recently expanded its commercialization of the GEM Premier 7000 with iQM3 blood gas testing system across Europe after a successful introduction in North America. This innovative system, which is now gaining traction in European markets, aims to address significant challenges in blood gas testing by providing rapid and accurate results.

A Breakthrough in Blood Gas Testing
The GEM Premier 7000 is distinct as it is the first blood gas testing solution that integrates hemolysis detection directly at the point of care. Hemolysis, a common preanalytical error in blood testing, can occur in up to 70% of cases, leading to inaccurate test results that can negatively impact patient management. The ability to detect hemolysis ensures clinicians can act on precise data, leading to better decision-making for patient treatment.

With the system's impressive processing speed, it delivers results in approximately 45 seconds, allowing healthcare professionals to make timely and informed choices about patient care. As noted by Remo Tazzi, Werfen's Vice President of Worldwide Marketing and Service, the successful implementation of the GEM Premier 7000 in North America has set a solid foundation for its introduction into European healthcare facilities.

Award-Winning Performance
The GEM Premier 7000's design and functionality have earned it multiple accolades, demonstrating its impact on improving diagnostic processes.

• - 2025 Edison Award: Silver Winner in Emergency and On-Site Health Solutions for its innovative integration of hemolysis detection.
• - 2024 Medical Device Network Excellence Awards: Including the Innovation Award, Research & Development Award, and Product Launch Award, highlighting its accuracy and efficiency in diagnostics.
• - 2024 RD 100 Award: Recognizing it among the top 100 new products and technologies introduced that year, showcasing its technological significance.
• - 2025 Premier Inc. Supplier Innovation Celebration Award: Acknowledging its lab-quality hemolysis detection and positive contributions to accurate patient management.

These honors reflect Werfen's commitment to innovation in specialized diagnostics, aiming to enhance clinical workflows and improve patient care outcomes.

The Challenge of Hemolysis
Despite the prevalence of hemolysis in various healthcare settings, its invisible nature often leads to difficulties in diagnosis and management. When red blood cells rupture, potassium and other cellular contents leak into the surrounding fluid. Such contamination can lead to falsely elevated potassium levels, resulting in misdiagnosis and possibly harmful management decisions. Eradicating these errors is crucial for hospitals aiming to achieve effective patient outcomes while minimizing costs associated with longer hospital stays and inappropriate treatments.

Future Prospects
Werfen's GEM Premier 7000 is a vital component of its broader Acute Care Diagnostics portfolio, aimed at improving patients' health outcomes and optimizing operational efficiencies in hospitals. Following the expansion into Europe, Werfen will hold a press conference during the Association for Diagnostics Laboratory Medicine (ADLM) Annual Meeting on July 30, 2025. This event will further detail the features and benefits of the GEM Premier 7000, alongside its success in enhancing diagnostic accuracy and efficiency in patient care.

Conclusion
With the GEM Premier 7000's robust capabilities and the recent awards underscoring its excellence, Werfen is poised to make significant contributions to the field of diagnostic medicine in Europe. As clinicians adopt this advanced technology, it will undoubtedly lead to improved patient outcomes and greater operational efficiencies in emergency and critical care settings. Werfen continues to pave the way for advancements in acute care diagnostics with its innovative solutions designed to meet the dynamic needs of healthcare providers.